Intellectual Property

Issued and pending patents cover composition of matter of the drug product and the use of TSC for the treatment of cancer in combination with radiation and/or chemotherapy. Eleven US patents have been issued; twenty six have issued abroad. Patents cover the major markets (US, EU, Japan), with key patent life until 2026, plus expected extensions until 2031. Seven year Orphan exclusivity provides additional protection, and a formulation patent provides protection for the TSC oral drug product until 2031, with possible extensions.